| Abstract | In the treatment of rheumatoid arthritis, specific drugs targeting disease-related proinflammatory cytokines such as tumour necrosis factor-alpha have been observed to show a positive impact on the clinical course of the disease. One of these drugs, etanercept, is a recombinant soluble fusion protein of tumour necrosis factor-alpha type 2 receptor. Although it has many well-established side effects, up to date there has not been any report of angio-oedema in the literature. Hence, we aimed to present clinical findings of a 59-year-old female patient who received etanercept for rheumatoid arthritis and developed angio-oedema during treatment, and to the discuss side effects of the drug within the context of current literature. |
| Authors | Omer Faruk Sendur, Yasemin Turan, Isil Karatas Berkit, Engin Tastaban
(Affiliation: Department of Physical Medicine and Rehabilitation, School of Medicine, Adnan Menderes University, Aydin, Turkey.)
|
| Journal | Basic & clinical pharmacology & toxicology
(Basic Clin Pharmacol Toxicol)
Vol. 104
Issue 6
Pg. 488-90
(Jun 2009)
ISSN: 1742-7843 [Electronic] Denmark |
| PMID | 19371261
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Antirheumatic Agents
- Immunoglobulin G
- Receptors, Tumor Necrosis Factor
- TNFR-Fc fusion protein
|
| Topics |
- Angioedema
(chemically induced)
- Antirheumatic Agents
(adverse effects, therapeutic use)
- Arthritis, Rheumatoid
(drug therapy)
- Female
- Humans
- Immunoglobulin G
(adverse effects, therapeutic use)
- Middle Aged
- Receptors, Tumor Necrosis Factor
(therapeutic use)
|
